Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.

British journal of cancer·2026
Same author

Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial.

The Lancet. Oncology·2026
Same author

Retrospective Study of Trametinib in Patients With Advanced <i>NF1</i>-Mutant Melanoma.

JCO precision oncology·2026
Same author

A Unique Case of Concomitant T-Prolymphocytic Leukemia and B-Cell Acute Lymphoblastic Leukemia.

EJHaem·2026
Same author

Correction: BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling.

eLife·2026
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Related Experiment Video

Updated: Apr 30, 2026

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.1K

Dabrafenib.

Radhika Kainthla1, Kevin B Kim, Gerald S Falchook

  • 1Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA, kainthla@bcm.edu.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|April 24, 2014
PubMed
Summary
This summary is machine-generated.

Dabrafenib effectively treats V600-mutant BRAF cancers like melanoma, improving survival. Research explores combination therapies to enhance efficacy and overcome drug resistance in aggressive tumors.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.3K

Related Experiment Videos

Last Updated: Apr 30, 2026

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.1K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • BRAF kinase mutations, particularly V600, drive aggressive tumor proliferation.
  • Metastatic melanoma frequently harbors V600-mutant BRAF, indicating a target for therapy.
  • Dabrafenib is a targeted therapy developed to inhibit V600-mutant BRAF kinase.

Purpose of the Study:

  • To evaluate the efficacy of dabrafenib in V600-mutant BRAF-driven cancers.
  • To assess dabrafenib's impact on response rates and progression-free survival.
  • To explore potential applications of dabrafenib in non-melanoma solid tumors and strategies to overcome resistance.

Main Methods:

  • Clinical trials were conducted to assess dabrafenib's efficacy and safety.
  • Patient outcomes, including response rates and progression-free survival, were analyzed.
  • Preliminary investigations into dabrafenib's role in non-melanoma tumors and combination strategies were performed.

Main Results:

  • Dabrafenib demonstrated improved response rates and median progression-free survival in patients with V600E BRAF mutations, including those with brain metastases.
  • The drug exhibits a well-tolerated toxicity profile and minimal drug interactions.
  • Emerging data suggest potential efficacy in non-melanoma V600-mutant solid tumors, warranting further investigation.

Conclusions:

  • Dabrafenib is an effective monotherapy for V600-mutant BRAF cancers, notably metastatic melanoma.
  • Drug resistance is a significant challenge, necessitating the development of combination strategies.
  • Future research should focus on optimizing dabrafenib combinations to improve patient outcomes and overcome resistance mechanisms.